What is the prevalence of diffuse large B-cell lymphoma in the US?

Updated: Aug 20, 2020
  • Author: Shipra Gandhi, MBBS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

After a striking increase in incidence rates between 1970 and 1995 (which may in part have reflected improved diagnosis), the rates of new non-Hodgkin lymphoma (NHL) cases stabilzed. From 2007-2016, rates of new cases fell on average 0.9% each year and death rates fell on average 2.2% each year. The current US age-adjusted rate is 19.6 cases per 100,000 person-years for both sexes. [32] The estimated rate for diffuse large cell lymphomas is approximately 4.68 cases per 100,000 person-years.

It is estimated that approximately 77,240 new cases of NHL will be diagnosed and 19,940 patients will die from NHL in 2020, despite currently available treatment. [33] Lymphomas are a heterogeneous group of malignancies with diverse biology, clinical behavior, and prognosis.

In general, lymphomas can be divided into two groups, Hodgkin lymphoma (HL) and NHL. While infrequent, HL (8,480 estimated new cases in 2020) is commonly diagnosed in younger patients and is curable with appropriate therapy in 85% of cases. In contrast, NHL is the seventh most common cancer in the United States, accounting for 4.3% of all cancers, and the eighth leading cause of cancer deaths, accounting for 3.3% of cancer-related deaths. [32] Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL diagnosed in the Western hemisphere, representing 30-40% of all NHL cases diagnosed every year in the United States. [34]

DLBCL typically affects patients in their sixth decade, except for primary mediastinal DLBCL variant, which affects mostly females in their late 20s or early 30s. Over the past decades, the incidence of DLBCL has been increasing, a trend that has been independent of the human immunodeficiency virus (HIV) infection epidemic. [35]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!